ANDA 91409, held by Zydus Pharms. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 91409 (Azelastine Hydrochloride), held by Zydus Pharms, was first approved by FDA on Aug 14, 2017, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.137MG/SPRAY · spray, metered;nasal | Azelastine Hydrochloride | Rx |
| Apr 30, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 14, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters